Dewpoint Therapeutics

Dewpoint Therapeutics

  • Founded: 2018
  • Location: Boston, MA
  • Employee range: 50 - 200
  • Clinical stage: RD
  • Therapy area: Ovarian cancer
  • Drug types: ONC, NEU, GEN, INF, CVV, LNG, NPH, END
  • Lead product: Undisclosed
  • Product link:
  • Funding: $150M C Feb 2022; $77M B Sep 2020; $60M A Jan 2019

job board

Short description:

Biomolecular Condensates

Drug notes:

Additional undisclosed programs RD colorectal cancer, AML, multiple neurological conditions, HIV, cardiopulmonary conditions, insulin resistance

Long description:

Dewpoint Therapeutics is the first company to apply the emerging understanding of biomolecular condensates to drug discovery. Condensates are important for cells to coordinate and control different biochemical processes by compartmentalizing them. Condensatopathies occur when proteins are incorrectly sequestered or excluded in condensates as is seen in neurodegeneration and cardiovascular disease. Dewpoint aims to prevent harmful protein sequestration by restoring healthy condensate properties and functions. Using a combination of genetics, imaging, mapping and medicinal chemistry, Dewpoint is using their condensate platform to produce novel targets that can then be used to develop life-changing medicines.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy